The Life Sciences industry operates in one of the fastest and most innovation-driven environments. 2018 has witnessed significant developments in technology and therapeutic practices. A number of new cell and gene therapies – including the first two CAR-T therapies for cancer – received EU approval, and both disruptive and ‘new mainstream’ technologies (such as AI) made significant steps forward into the sector.
The pharmaceutical and medical device sectors are also among the most heavily regulated. Life Sciences companies face significant challenges in managing regulatory compliance in an environment where regulation constantly evolves. Moreover, the sector moves so fast that it is hard for regulation to keep up with the pace of technological development.
Read more »